Apixaban would still cost patients 9 times more through the Eliquis 360 Support program than with commercial insurance.

Pfizer (PFE), in collaboration with Bristol Myers Squibb, has introduced a direct-to-patient option for Eliquis®, potentially ...

Apixaban tied to less stroke and bleeding in patients with/without dementia vs. dabigatran, rivaroxaban or warfarin. Image: Adobe Stock “The prescribing decisions for oral anticoagulants need to ...

The program will provide direct shipping to patients across all 50 states and Puerto Rico, offering an additional, simplified option for accessing Eliquis and full transparency into the associated ...

Patients assigned apixaban had significantly lower incidence rates of hospitalization for recurrent VTE vs. those assigned warfarin (9.8 per 1,000 person years vs. 13.5 per 1,000 person years; HR ...

"Apixaban may be better for a patient with a history of GI bleeding because there's less GI bleeding, but the guidelines don't necessarily spell those things out," Beavers said.

Apixaban has also been evaluated for stroke prevention in AF in two Phase III trials, one of which was recently completed. Both include patients with one or more additional stroke risk factors ( ...

Unlike rivaroxaban, apixaban can be administered with or without food so that patients do not have to plan medication around a meal. In patients with CKD, label indications advise not prescribing the ...

Apixaban was also associated with a 49% lower risk of gastrointestinal or intracranial bleeding vs rivaroxaban (HR, 0.51; 95% CI, 0.41-0.62).

Asundexian 50 mg daily was inferior to apixaban for stroke and systemic embolism prevention in high-risk patients with atrial fibrillation (AF), according to late-breaking research presented in a ...

In the overall trial, apixaban was not superior to standard care for the prevention of clinical events, irrespective of the need for oral anticoagulation. In the substudy, investigators evaluated the ...

ABSTRACT. Objectives: To investigate the journey to oral anticoagulant (OAC) access following formulary-related rejection of apixaban (Eliquis) and evaluate characteristics associated with failure ...